Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

cemiplimab

- PMLiVE

Moderna and Merck announce data from melanoma combination therapy study

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

- PMLiVE

Regeneron’s Libtayo receives EC approval for skin cancer

Phase 3 trial results showed the drug significantly improved disease-free survival

regeneron headquarters

Regeneron’s Lynozyfic granted FDA accelerated approval to treat multiple myeloma

More than 36,000 new cases of the blood cancer are expected to be diagnosed in the US this year

regeneron headquarters

Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

regeneron headquarters

Regeneron to acquire human genetics company 23andMe for $256m

The agreement comes two months after 23andMe filed for bankruptcy protection

- PMLiVE

NHS programme to give melanoma patients fast-track access to skin cancer vaccine

The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

regeneron headquarters

Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma

More than 35,000 new cases of the blood cancer are diagnosed every year in Europe

regeneron headquarters

Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer

Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year

- PMLiVE

Merck shares positive ten-year results for Keytruda in advanced melanoma

More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year

regeneron headquarters

Regeneron’s Libtayo shows durable survival benefits in phase 3 lung cancer study

Non-small cell lung cancer accounts for up to 85% of all lung cancer cases

regeneron headquarters

Regeneron’s odronextamab recommended by CHMP to treat certain lymphomas

Follicular lymphoma and diffuse large B-cell lymphoma are collectively responsible for an estimated 283,000 global cases every year

- PMLiVE

Moderna/Merck share positive three-year results for investigational skin cancer vaccine

More than 100,000 new cases of melanoma are expected to be diagnosed in the US in 2024

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links